EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis

NACompletedINTERVENTIONAL
Enrollment

317

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions
Cystic Fibrosis-related Diabetes
Interventions
DIAGNOSTIC_TEST

Oral glucose tolerance test

oral glucose solution is given by mouth, blood is drawn prior to the administration of the oral glucose beverage and then at timed intervals afterward. This is the standard test to diagnosis cystic fibrosis related diabetes mellitus. However, this study will have more time points than standard screening for cystic fibrosis related diabetes mellitus

DIAGNOSTIC_TEST

Continuous glucose monitoring

a device is placed on the subject's arm that continuously monitors subcutaneous glucose levels for up to 10 days

DIAGNOSTIC_TEST

Dexa scan

low dose x-rays are used to measure the subject's bone density. This is the standard test to diagnose osteoporosis

Trial Locations (4)

52242

University of Iowa, Iowa City

55455

University of Minnesota, Minneapolis

63110

Washington University St. Louis, St Louis

80045

University of Colorado, Aurora

All Listed Sponsors
lead

Katie Larson Ode

OTHER

NCT03650712 - EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis | Biotech Hunter | Biotech Hunter